NZ711566A - Formulations with reduced oxidation - Google Patents

Formulations with reduced oxidation

Info

Publication number
NZ711566A
NZ711566A NZ711566A NZ71156614A NZ711566A NZ 711566 A NZ711566 A NZ 711566A NZ 711566 A NZ711566 A NZ 711566A NZ 71156614 A NZ71156614 A NZ 71156614A NZ 711566 A NZ711566 A NZ 711566A
Authority
NZ
New Zealand
Prior art keywords
protein
formulations
hydroxy
oxidation
methods
Prior art date
Application number
NZ711566A
Other languages
English (en)
Inventor
Sreedhara Alavattam
Mary Mallaney
Parbir Grewal
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to NZ751543A priority Critical patent/NZ751543B2/en
Publication of NZ711566A publication Critical patent/NZ711566A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Lubricants (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ711566A 2013-03-13 2014-03-13 Formulations with reduced oxidation NZ711566A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ751543A NZ751543B2 (en) 2013-03-13 2014-03-13 Formulations with reduced oxidation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780845P 2013-03-13 2013-03-13
US201361909813P 2013-11-27 2013-11-27
PCT/US2014/026841 WO2014160495A1 (en) 2013-03-13 2014-03-13 Formulations with reduced oxidation

Publications (1)

Publication Number Publication Date
NZ711566A true NZ711566A (en) 2020-06-26

Family

ID=51625442

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ711566A NZ711566A (en) 2013-03-13 2014-03-13 Formulations with reduced oxidation

Country Status (23)

Country Link
EP (1) EP2968466B1 (enExample)
JP (3) JP6389236B2 (enExample)
KR (1) KR102237885B1 (enExample)
CN (2) CN104968362B (enExample)
AU (3) AU2014243700B2 (enExample)
CA (2) CA3113172A1 (enExample)
DK (1) DK2968466T3 (enExample)
ES (1) ES2688895T3 (enExample)
HR (1) HRP20181504T1 (enExample)
HU (1) HUE039948T2 (enExample)
IL (2) IL269947B (enExample)
LT (1) LT2968466T (enExample)
MX (2) MX369671B (enExample)
MY (2) MY174679A (enExample)
NZ (1) NZ711566A (enExample)
PL (1) PL2968466T3 (enExample)
PT (1) PT2968466T (enExample)
RS (1) RS57813B1 (enExample)
RU (1) RU2707092C2 (enExample)
SG (2) SG11201507043SA (enExample)
SI (1) SI2968466T1 (enExample)
WO (1) WO2014160495A1 (enExample)
ZA (2) ZA201506876B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
KR102317151B1 (ko) * 2013-03-13 2021-10-26 제넨테크, 인크. 감소된 산화를 갖는 제제
AR095399A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida, método
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN115998859A (zh) 2016-06-27 2023-04-25 莫佛塞斯公司 抗-cd19抗体制剂
CN111194233A (zh) * 2017-10-13 2020-05-22 株式会社田村特科 有害物质处理方法及臭氧产生装置
BR112021002130A2 (pt) * 2018-08-08 2021-05-04 Genentech, Inc. formulação líquida, artigo de fabricação ou kit e método para reduzir a oxidação de um polipeptídeo

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2332893T3 (es) 1996-08-30 2010-02-15 Upfront Chromatography A/S Aislamiento de inmunoglobulinas.
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
CA2368734C (en) 1999-03-30 2005-08-23 Japan Tobacco Inc. Method for preparing monoclonal antibody
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1260230A4 (en) * 2000-02-29 2008-08-06 Chugai Pharmaceutical Co Ltd LONG-TERM STABILIZED PREPARATIONS
AU1297002A (en) * 2000-09-15 2002-03-26 Scripps Research Inst Methods and compositions relating to hydrogen peroxide and superoxide productionby antibodies
US6933123B2 (en) * 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
CA2447114A1 (en) 2001-05-16 2002-11-21 Abgenix, Inc. Human antipneumococcal antibodies from non-human animals
DK1425389T3 (da) 2001-08-23 2012-01-30 Genmab As Interleukin-15-(IL-15)-specifikke humane antistoffer
ATE414537T1 (de) * 2001-08-29 2008-12-15 Chugai Pharmaceutical Co Ltd Antikörper enthaltende stabilisierte zubereitungen
US20040116350A1 (en) * 2001-09-17 2004-06-17 Paul Wentworth Jr Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
CN1761482A (zh) 2003-01-17 2006-04-19 纽约州立大学研究基金会 与胰腺癌相关的抗原、针对它的抗体以及诊断和治疗方法
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004270103B2 (en) 2003-05-21 2012-02-23 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies against Bacillusanthracis protective antigen
US7709604B2 (en) * 2003-12-18 2010-05-04 The Scripps Research Institute Selective incorporation of 5-hydroxytryptophan into proteins in mammalian cells
WO2007095288A2 (en) * 2006-02-13 2007-08-23 Nektar Therapeutics Methionine-containing protein or peptide compositions and methods of making and using
CN101438158A (zh) * 2006-03-06 2009-05-20 阿穆尼克斯股份有限公司 遗传包和其应用
JP2007319124A (ja) * 2006-06-02 2007-12-13 Nippon Tablet Kk 健康食品
MY154869A (en) * 2007-01-16 2015-08-14 Ipintl Llc Composition for treating metabolic syndrome
SG10201608068SA (en) * 2008-04-01 2016-11-29 Antipodean Pharmaceuticals Inc Compositions And Methods For Skin Care
EP2321640B1 (en) * 2008-08-21 2016-11-30 Immunogenics LLC Formulation for oral administration of proteins
EP2334323A2 (en) * 2008-09-10 2011-06-22 F. Hoffmann-La Roche AG Compositions and methods for the prevention of oxidative degradation of proteins
EP2331090B1 (en) * 2008-09-19 2018-01-03 Pfizer Inc. Stable liquid antibody formulation
ES2751381T3 (es) * 2010-06-24 2020-03-31 Hoffmann La Roche Composiciones y procedimientos que contienen alquilglucósidos para estabilizar formulaciones que contienen proteínas
RU2447448C1 (ru) * 2010-08-30 2012-04-10 Государственное образовательное учреждение высшего профессионального образования "Оренбургский государственный университет" Способ стабилизации антител в водных растворах
EP2717698A4 (en) * 2011-06-09 2015-01-07 Requis Pharmaceuticals Inc ANTI-HISTAMINE IN COMBINATION WITH FOOD SUPPLEMENTS FOR IMPROVED HEALTH
EP2726495B1 (en) * 2011-06-28 2019-03-06 Leukocare Ag Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide

Also Published As

Publication number Publication date
CA2904166C (en) 2021-05-18
JP6389236B2 (ja) 2018-09-12
EP2968466B1 (en) 2018-07-25
HRP20181504T1 (hr) 2018-11-02
EP2968466A1 (en) 2016-01-20
SI2968466T1 (sl) 2018-10-30
LT2968466T (lt) 2018-10-10
KR20150130397A (ko) 2015-11-23
AU2019202464B2 (en) 2020-12-10
MX369671B (es) 2019-11-15
AU2019202464A1 (en) 2019-05-02
IL269947A (enExample) 2019-12-31
HK1211219A1 (en) 2016-05-20
PL2968466T3 (pl) 2018-11-30
MY174679A (en) 2020-05-06
SG11201507043SA (en) 2015-10-29
KR102237885B1 (ko) 2021-04-07
RU2707092C2 (ru) 2019-11-22
IL269947B (en) 2022-08-01
RU2015143548A (ru) 2017-04-20
JP2020164531A (ja) 2020-10-08
MX2019013560A (es) 2020-01-20
IL240933A0 (en) 2015-11-30
MX2015011432A (es) 2016-04-27
RS57813B1 (sr) 2018-12-31
CA2904166A1 (en) 2014-10-02
JP2018150317A (ja) 2018-09-27
CA3113172A1 (en) 2014-10-02
CN104968362B (zh) 2018-12-14
IL240933B (en) 2019-10-31
NZ751543A (en) 2020-09-25
ZA201906057B (en) 2022-04-28
PT2968466T (pt) 2018-10-22
AU2014243700A1 (en) 2015-10-08
ZA201506876B (en) 2019-12-18
SG10201705525VA (en) 2017-08-30
WO2014160495A1 (en) 2014-10-02
DK2968466T3 (en) 2018-10-22
EP2968466A4 (en) 2016-10-26
AU2014243700B2 (en) 2019-01-24
CN110075293A (zh) 2019-08-02
JP2016520521A (ja) 2016-07-14
BR112015022484A2 (pt) 2017-07-18
MY199135A (en) 2023-10-17
CN104968362A (zh) 2015-10-07
AU2021201366A1 (en) 2021-03-18
HUE039948T2 (hu) 2019-02-28
ES2688895T3 (es) 2018-11-07

Similar Documents

Publication Publication Date Title
NZ711566A (en) Formulations with reduced oxidation
NZ763528A (en) Heterocyclic gpr119 agonist compounds
PH12016502479A1 (en) Formulated receptor polypeptides and related methods
PH12016500739B1 (en) Inhibitors of the fibrolast growth factor receptor
MX2016006891A (es) Metodos utiles en la sintesis de analogos de halicondrina b.
EP4279071A3 (en) Novel cannabinoid formulations
PH12017500660A1 (en) Novel compositions, uses and methods for making them
MX2017006694A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
WO2015120062A8 (en) Therapeutic compounds and compositions
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MX2018015247A (es) Heterociclos de biarilmetilo.
MX2017011116A (es) Composiciones novedosas, usos y metodos para hacerlas.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2015011433A (es) Formulaciones con oxidacion reducida.
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
MX2019012665A (es) Compuestos organicos.
IN2013MU00665A (enExample)
MX2019005294A (es) Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos.
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
MX2018005134A (es) Formulacion de factor viii (fviii).
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.
PT3415142T (pt) Composição para o tratamento de blefarite que contém terpinen-4-ol

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2022 BY THOMSON REUTERS

Effective date: 20210206

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2023 BY THOMSON REUTERS

Effective date: 20220302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2024 BY THOMSON REUTERS

Effective date: 20230201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2025 BY ANAQUA SERVICES

Effective date: 20240220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2026 BY ANAQUA SERVICES

Effective date: 20250219